CoreyAllanCarterMD(He/Him)
Oncology • South San Francisco, CAHead & Neck Cancer, Melanoma, Thoracic Cancer
Global Development Leader GU
Dr. Carter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Dna Way
South San Francisco, CA 94080Phone+1 240-408-0425
Education & Training
National Capital ConsortiumFellowship, Hematology and Medical Oncology, 2006 - 2009
UniforMed Services University of the Health Sciences F. Edward Hebert School of MedicineClass of 2003
Certifications & Licensure
VA State Medical License 2004 - 2026
Clinical Trials
- A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
- Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
- Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade.Habib Hamidi, Yasin Senbabaoglu, Niha Beig, Juliette Roels, Cyrus Manuel
Cancer Cell. 2024-12-09 - Correlation of safety and efficacy of atezolizumab therapy across indications.Gonzalo Durán-Pacheco, G Scott Chandler, Vidya Maiya, Mark A Socinski, Guru Sonpavde
Journal for Immunotherapy of Cancer. 2024-11-12 - 12 citationsA Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.Brant A Inman, Noah M Hahn, Kelly Stratton, Ryan Kopp, Alex Sankin
European Urology Oncology. 2023-06-01
Press Mentions
EpicentRx Appoints Senior Life Science Financial Executive Dr. Franck BrinkhausDecember 4th, 2019- EpicentRx Initiates Dosing in Phase 3 Trial of Immunotherapy RRx-001 for Third-Line Small Cell Lung CancerNovember 5th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
